RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 4

Registered title, quoted from ClinicalTrials.gov

Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Zhengzhou University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)First Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06609304, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Previous treatment with anti-CD19/CD3 or other anti-CD19 therapies;

    Exclusion criterion 7

  3. Eastern Cooperative Oncology Group (ECOG) Physical Status Score of 0 or 1; 8. Absence of CNS lymphoma;

    Inclusion criterion 7

  4. Negative blood/urine pregnancy test in women of childbearing age.

    Inclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06609304, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Understand and voluntarily sign the informed consent form;
  • 18-70 years of age (inclusive);
  • Previously untreated CD19-positive large B-cell lymphoma;
  • Anticipated survival ≥12 weeks;
  • Adequate bone marrow reserve prior to apheresis
  • Appropriate organ function:
  • Eastern Cooperative Oncology Group (ECOG) Physical Status Score of 0 or 1; 8. Absence of CNS lymphoma;
  • Negative blood/urine pregnancy test in women of childbearing age.

Exclusion Criteria:

  • History of allergy to any of the components of the cell product;
  • History of stem cell transplantation;
  • History of organ transplantation;
  • Presence of active infections;
  • Current or history of central nervous system disorders;
  • Previous treatment with other modified T-cell therapy;
  • Previous treatment with anti-CD19/CD3 or other anti-CD19 therapies;
  • Malignancies other than those indicated for this trial;
  • History of any prior systemic immune checkpoint therapy;
  • History of short-acting cell growth factors or haematopoietic agonists/stimulants ;
  • History of a live vaccine within 3 months prior to screening;.

Quoted from ClinicalTrials.gov, NCT06609304, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06609304, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06609304